Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, induces respiratory frequency plasticity that is resistant to inflammation in neonatal rat in vitro preparations
Respiratory Physiology & Neurobiology · 2025
DOI: 10.1016/j.resp.2025.104435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiratory Physiology & Neurobiology, 2025. Verfasst von Stephen M Johnson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States. Electronic address…. Hauptthemen laut MEDLINE: Aminopyridines, Phosphodiesterase 4 Inhibitors, Benzamides, Inflammation. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Premature and newborn infants often have prolonged apneas and are susceptible to bacterial infections that further disrupt breathing. Phoshodiesterase-4 (PDE4) inhibitor drugs increase inspiratory motor activity and appear to induce a long-lasting increase in inspiratory frequency ("frequency plasticity"). To test whether a PDE4 inhibitor drug induces frequency plasticity, neonatal rat brainstem-spinal cords were isolated and exposed to bath-applied roflumilast (10 min, 0.02-1.0 µM). Roflumilast acutely increased burst frequency and induced frequency plasticity in a concentration-dependent manner. Blockade of protein kinase A (PKA) or exchange protein activated by cAMP (EPAC) signaling pathways abolished the induction, but not the maintenance, of roflumilast-induced frequency plasticity. Brainstem-spinal cords isolated from neonatal rats injected with lipopolysaccharide (LPS, 0.1 mg/kg, 3 h prior) expressed frequency plasticity following bath-applied roflumilast at 0.05-0.5 µM, but not at lower concentrations. This shows that roflumilast-induced frequency plasticity is largely resistant to LPS-induced inflammation. Thus, roflumilast increases inspiratory burst frequency acutely and induces frequency plasticity even during ongoing inflammation, which could have important clinical implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States. Electronic address: stephen.m.johnson@wisc.edu.
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Johnson, S. M., Rastas, J. P., Desai, P. S., Baker, T. L., & Watters, J. J. (2025). Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, induces respiratory frequency plasticity that is resistant to inflammation in neonatal rat in vitro preparations. Respiratory Physiology & Neurobiology. https://doi.org/10.1016/j.resp.2025.104435
Vancouver
Johnson SM, Rastas JP, Desai PS, Baker TL, Watters JJ. Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, induces respiratory frequency plasticity that is resistant to inflammation in neonatal rat in vitro preparations. Respiratory Physiology & Neurobiology. 2025. doi:10.1016/j.resp.2025.104435
BibTeX
@article{Johnson2025,
author = {Johnson, Stephen M and Rastas, Jacob P and Desai, Pujal S and Baker, Tracy L and Watters, Jyoti J},
title = {Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, induces respiratory frequency plasticity that is resistant to inflammation in neonatal rat in vitro preparations},
journal = {Respiratory Physiology & Neurobiology},
year = {2025},
doi = {10.1016/j.resp.2025.104435}
}
EUVIMED